Literature DB >> 32456723

Quantitative cardiac magnetic resonance T2 imaging offers ability to non-invasively predict acute allograft rejection in children.

Neeta Sethi1, Ashish Doshi1,2, Tina Doshi3, Russell Cross1, Ileen Cronin1, Elena Amin4, Joshua Kanter1, Janet Scheel5, Sairah Khan1, Adrienne Campbell-Washburn6, Laura Olivieri1.   

Abstract

BACKGROUND: Monitoring for acute allograft rejection improves outcomes after cardiac transplantation. Endomyocardial biopsy is the gold standard test defining rejection, but carries risk and has limitations. Cardiac magnetic resonance T2 mapping may be able to predict rejection in adults, but has not been studied in children. Our aim was to evaluate T2 mapping in identifying paediatric cardiac transplant patients with acute rejection.
METHODS: Eleven paediatric transplant patients presenting 18 times were prospectively enrolled for non-contrast cardiac magnetic resonance at 1.5 T followed by endomyocardial biopsy. Imaging included volumetry, flow, and T2 mapping. Regions of interest were manually selected on the T2 maps using the middle-third technique in the left ventricular septal and lateral wall in a short-axis and four-chamber slice. Mean and maximum T2 values were compared with Student's t-tests analysis.
RESULTS: Five cases of acute rejection were identified in three patients, including two cases of grade 2R on biopsy and three cases of negative biopsy treated for clinical symptoms attributed to rejection (new arrhythmia, decreased exercise capacity). A monotonic trend between increasing T2 values and higher biopsy grades was observed: grade 0R T2 53.4 ± 3 ms, grade 1R T2 54.5 ms ± 3 ms, grade 2R T2 61.3 ± 1 ms. The five rejection cases had significantly higher mean T2 values compared to cases without rejection (58.3 ± 4 ms versus 53 ± 2 ms, p = 0.001).
CONCLUSIONS: Cardiac magnetic resonance with quantitative T2 mapping may offer a non-invasive method for screening paediatric cardiac transplant patients for acute allograft rejection. More data are needed to understand the relationship between T2 and rejection in children.

Entities:  

Keywords:  Paediatric; T2 mapping; allograft rejection; cardiac magnetic resonance; heart transplant

Year:  2020        PMID: 32456723     DOI: 10.1017/S104795112000116X

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  5 in total

1.  Cardiac Magnetic Resonance Imaging Noninvasively Detects Rejection in Pediatric Heart Transplant Recipients.

Authors:  Jonathan H Soslow; Justin Godown; David W Bearl; Kimberly Crum; James C Slaughter; Kristen George-Durrett; Kak-Chen Chan; Maryanne Chrisant; Debra Dodd; Lazaro Hernandez
Journal:  Circ Cardiovasc Imaging       Date:  2022-03-30       Impact factor: 8.589

Review 2.  T2 mapping in myocardial disease: a comprehensive review.

Authors:  Aaron T O'Brien; Katarzyna E Gil; Juliet Varghese; Orlando P Simonetti; Karolina M Zareba
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-06       Impact factor: 6.903

3.  Multi-parametric cardiovascular magnetic resonance with regadenoson stress perfusion is safe following pediatric heart transplantation and identifies history of rejection and cardiac allograft vasculopathy.

Authors:  Nazia Husain; Kae Watanabe; Haben Berhane; Aditi Gupta; Michael Markl; Cynthia K Rigsby; Joshua D Robinson
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-22       Impact factor: 5.364

Review 4.  Insight into Noninvasive Radiological Modalities to Detect Heart Transplant Rejection.

Authors:  Dhruva Sharma; Ganapathy Subramaniam; Neha Sharma; Preksha Sharma; Pooja Sharma
Journal:  Indian J Radiol Imaging       Date:  2022-01-11

5.  Native T1 mapping detects both acute clinical rejection and graft dysfunction in pediatric heart transplant patients.

Authors:  Devika P Richmann; Nyshidha Gurijala; Jason G Mandell; Ashish Doshi; Karin Hamman; Christopher Rossi; Avi Z Rosenberg; Russell Cross; Joshua Kanter; John T Berger; Laura Olivieri
Journal:  J Cardiovasc Magn Reson       Date:  2022-10-03       Impact factor: 6.903

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.